Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TERM: OBE001 in threatened preterm labor
NCT02326142Phase 2Terminated
- Sponsor
- ObsEva SA
- Start
- Mar 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of ebopiprant in Preterm labor (PTL), sponsored by ObsEva SA. Primary endpoint: Incidence of women delivering within 7 days post first dose. Started Mar 2015; status: terminated.
02
Drugs
ebopiprant
03
Conditions
Preterm labor (PTL)
Beyond the preview
Go deeper on NCT02326142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326142.